Dravet syndrome is rare, drug-resistant epilepsy that begins in the first year of life in an otherwise healthy infant. It is lifelong. It usually presents with a prolonged seizure with a fever that affects one side of the body. Most cases are due to severe SCN1A gene mutations.
Dravet syndrome treatment includes anti-epileptic drugs that are usually the first medicinal solutions used for the treatment. This type of anti-epileptic medication works by altering the actions of certain neurotransmitters in the brain and, as a result, reduces seizures and other side effects associated with them. While this is often effective for some people, especially when compared to the seizure-provoking effect of certain anti-epileptic drugs, it does have some serious side effects and should only be prescribed under close medical supervision. Patients who are given Phenytoin to treat their Dravet Syndrome should not take any other drugs for approximately four to six weeks after ceasing of medication.
Tagar is found to be effective in managing convulsions due to its anticonvulsant property. Certain chemicals present in Tagar help to minimize the severity of convulsions and also reduces their frequency. These anticonvulsant compounds also prevent epilepsy. Tagar, however, has its own set of side effects, including high blood pressure, vomiting, and diarrhea, which can potentially make Dravet Syndrome even more difficult to manage. These side effects can make it impossible for patients to continue with their daily routines and activities. In addition, Tagar can cause further health problems if taken at the wrong dosage.
Tags
Blogs